Literature DB >> 29066139

Role of BI-RADS Ultrasound Subcategories 4A to 4C in Predicting Breast Cancer.

Miguel Angelo Spinelli Varella1, Jackson Teixeira da Cruz2, Andrea Rauber3, Ivana Santos Varella4, James Freitas Fleck5, Luis Fernando Moreira6.   

Abstract

BACKGROUND: The Breast Imaging Reporting and Data System (BI-RADS) ultrasound (US) categorization revised in 2013 by the American College of Radiology resulted in unquestionable standardization of reports and confirmed category 3 and 5 as benign and malignant lesions, respectively. In contrast, suspected images (category 4) have subcategorization criteria, although theses have been detailed difficult to apply. The aim of the present study was to determine the role of the US 4A to 4C BI-RADS subcategories in predicting malignancy. PATIENTS AND METHODS: We performed a cross-sectional study of diagnostic tests to estimate the performance of the US BI-RADS categorization to clearly differentiate benign from malignant lesions. A total of 975 US examinations performed at the Hospital Femina, Grupo Hospitalar Conceição teaching hospitals from January 2012 through March 2015 were included in the present study. The US BI-RADS lexicon was used to classify the examination findings. Suspicious lesions underwent core needle biopsy, and the US and histology reports were compared to determine the performance using receiver operating characteristic curves.
RESULTS: Overall, the BI-RADS US categorization showed good discriminating accuracy with a receiver operating characteristic curve of 91% (95% confidence interval [CI], 88%-93%). However, BI-RADS subcategory 4b had a positive predictive value of 25% (95% CI, 20%-31%) and subcategory 4A had a positive predictive value of only 6% (95% CI, 3.5%-9.8%).
CONCLUSION: Our results have shown that US BI-RADS subcategories 4A and 4B are clearly unfit for use in screening tests, because they cannot rule out the need for biopsy. Therefore, management will not be improved by subcategorizing category 4, because all suspicious lesions will still require definite biopsy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Accuracy; BI-RADS US; Breast biopsy; Breast lump; Breast neoplasm

Mesh:

Year:  2017        PMID: 29066139     DOI: 10.1016/j.clbc.2017.09.002

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  5 in total

1.  Prospective assessment of adjunctive ultrasound-guided diffuse optical tomography in women undergoing breast biopsy: Impact on BI-RADS assessments.

Authors:  Steven P Poplack; Catherine A Young; Ian S Hagemann; Jingqin Luo; Cheryl R Herman; Kimberly Wiele; Shuying Li; Yifeng Zeng; Matthew F Covington; Quing Zhu
Journal:  Eur J Radiol       Date:  2021-11-13       Impact factor: 4.531

2.  Machine learning-based diagnostic evaluation of shear-wave elastography in BI-RADS category 4 breast cancer screening: a multicenter, retrospective study.

Authors:  Yi Tang; Minjie Liang; Li Tao; Minjun Deng; Tianfu Li
Journal:  Quant Imaging Med Surg       Date:  2022-02

3.  Development and External Validation of a Simple-To-Use Dynamic Nomogram for Predicting Breast Malignancy Based on Ultrasound Morphometric Features: A Retrospective Multicenter Study.

Authors:  Qingling Zhang; Qinglu Zhang; Taixia Liu; Tingting Bao; Qingqing Li; You Yang
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

4.  Mammography breast density: an effective supplemental modality for the precise grading of ultrasound BI-RADS 4 categories.

Authors:  Wei-Min Li; Qiu-Wei Sun; Xiao-Fang Fan; Jun-Chao Zhang; Ting Xu; Qi-Qi Shen; Lei Jia
Journal:  Gland Surg       Date:  2021-06

5.  The Vascular Index of Superb Microvascular Imaging Can Improve the Diagnostic Accuracy for Breast Imaging Reporting and Data System Category 4 Breast Lesions.

Authors:  Si-Man Cai; Hong-Yan Wang; Xiao-Yan Zhang; Li Zhang; Qing-Li Zhu; Jian-Chu Li; Qiang Sun; Yu-Xin Jiang
Journal:  Cancer Manag Res       Date:  2020-03-11       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.